The latest price of avatrombopag (Avatrombopag, Sucoxin) in 2025

Avatrombopag/Avatrombopag is an orally administered thrombopoietin (TPO) receptor agonist that can mimic the biological effects of TPO on megakaryocyte development and maturation, thereby effectively increasing platelet counts. In clinical studies, avatrombopag performed better than placebo in reducing patients' platelet transfusion requirements and bleeding rescue procedures, and is therefore widely recognized as an effective option for the treatment of specific thrombocytopenias.

Avatrombopag has been approved by the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and the State Food and Drug Administration. It is suitable for the treatment of severe thrombocytopenia in adult patients with chronic liver disease who plan to undergo invasive surgery. It can also treat thrombocytopenia in adult patients with chronic immune thrombocytopenia (ITP), especially those who have had poor response to previous treatments.

ChronicITP is a rare autoimmune disease characterized by a significant decrease in the number of platelets, which can easily lead to bleeding. The use of avatrombopag provides these patients with a new treatment option, providing important support to improve their quality of life and reduce the risk of bleeding. Therefore, the application of avatrombopag in the field of hematology has attracted increasing attention and has become an important part of the treatment plan for patients with chronic liver disease and chronic ITP. By increasing platelet counts, avatrombopag not only helps patients successfully complete surgery, but also reduces the risk of complications caused by insufficient platelets.

The original drug of avatrombopag has been launched in China and is included in Class B medical insurance, but reimbursement is subject to patient conditions. Common specifications include20mg*15 tablets and 20mg*10 tablets per box, and the price may be around 7,000 yuan. Overseas, the price of the original drug is even more expensive. However, there are already generic drugs on the market overseas, and their drug ingredients are basically the same as the original drugs. For example, Laos Pharmaceutical’s 20mg*30 tablets are priced at about more than 500 yuan, which may fluctuate due to exchange rates.

References:https://www.sobi.com/en/press-releases/sobi-launch-dopteletr-avatrombopag-europe-1861948